101 related articles for article (PubMed ID: 23379426)
41. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein.
Bosch I; Dunussi-Joannopoulos K; Wu RL; Furlong ST; Croop J
Biochemistry; 1997 May; 36(19):5685-94. PubMed ID: 9153408
[TBL] [Abstract][Full Text] [Related]
42. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
43. [The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma].
De Moerloose B
Verh K Acad Geneeskd Belg; 2005; 67(1):45-54. PubMed ID: 15828306
[TBL] [Abstract][Full Text] [Related]
44. Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin.
Vilas-Boas V; Silva R; Nunes C; Reis S; Ferreira L; Vieira C; Carvalho F; Bastos Mde L; Remião F
Toxicol Lett; 2013 Jul; 220(3):259-66. PubMed ID: 23685082
[TBL] [Abstract][Full Text] [Related]
45. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells.
Kamau SW; Krämer SD; Günthert M; Wunderli-Allenspach H
In Vitro Cell Dev Biol Anim; 2005; 41(7):207-16. PubMed ID: 16223335
[TBL] [Abstract][Full Text] [Related]
46. Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein.
Tempestilli M; Elisei F; Cimini E; D'Avolio A; Grassi G; Nicastri E; Narciso P; Martini F; Alonzi T; Paolo Pucillo L
J Antimicrob Chemother; 2014 Jul; 69(7):1760-6. PubMed ID: 24648507
[TBL] [Abstract][Full Text] [Related]
47. A lipid-specific toxin reveals heterogeneity of sphingomyelin-containing membranes.
Ishitsuka R; Yamaji-Hasegawa A; Makino A; Hirabayashi Y; Kobayashi T
Biophys J; 2004 Jan; 86(1 Pt 1):296-307. PubMed ID: 14695271
[TBL] [Abstract][Full Text] [Related]
48. Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer.
Negi LM; Jaggi M; Joshi V; Ronodip K; Talegaonkar S
Int J Biol Macromol; 2015 Feb; 73():222-35. PubMed ID: 25478964
[TBL] [Abstract][Full Text] [Related]
49. [Study on preparation of gypenosides liposomes composed of sphingomyelin and cholesterol and its quality evaluation].
Fan Y
Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(22):3875-9. PubMed ID: 24558868
[TBL] [Abstract][Full Text] [Related]
50. Visualization of the heterogeneous membrane distribution of sphingomyelin associated with cytokinesis, cell polarity, and sphingolipidosis.
Makino A; Abe M; Murate M; Inaba T; Yilmaz N; Hullin-Matsuda F; Kishimoto T; Schieber NL; Taguchi T; Arai H; Anderluh G; Parton RG; Kobayashi T
FASEB J; 2015 Feb; 29(2):477-93. PubMed ID: 25389132
[TBL] [Abstract][Full Text] [Related]
51. Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells.
Storch CH; Klimm HD; Heinrich T; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):135-43. PubMed ID: 17653693
[TBL] [Abstract][Full Text] [Related]
52. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.
Swerts K; de Moerloose B; Dhooge C; Noens L; Laureys G; Benoit Y; Philippé J
Leuk Lymphoma; 2004 Nov; 45(11):2221-8. PubMed ID: 15512810
[TBL] [Abstract][Full Text] [Related]
53. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance.
Gong J; Luk F; Jaiswal R; George AM; Grau GE; Bebawy M
Eur J Pharmacol; 2013 Dec; 721(1-3):116-25. PubMed ID: 24095666
[TBL] [Abstract][Full Text] [Related]
54. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment.
Modok S; Heyward C; Callaghan R
J Lipid Res; 2004 Oct; 45(10):1910-8. PubMed ID: 15258203
[TBL] [Abstract][Full Text] [Related]
55. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
Webb MS; Harasym TO; Masin D; Bally MB; Mayer LD
Br J Cancer; 1995 Oct; 72(4):896-904. PubMed ID: 7547237
[TBL] [Abstract][Full Text] [Related]
56. Decrease of P-glycoprotein activity in K562/ADR cells by MbetaCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts.
Reungpatthanaphong P; Marbeuf-Gueye C; Le Moyec L; Salerno M; Garnier-Suillerot A
J Bioenerg Biomembr; 2004 Dec; 36(6):533-43. PubMed ID: 15692732
[TBL] [Abstract][Full Text] [Related]
57. Sphingomyelins Prevent Propagation of Lipid Peroxidation-LC-MS/MS Evaluation of Inhibition Mechanisms.
Coliva G; Lange M; Colombo S; Chervet JP; Domingues MR; Fedorova M
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326262
[TBL] [Abstract][Full Text] [Related]
58. Acid-Sphingomyelinase Triggered Fluorescently Labeled Sphingomyelin Containing Liposomes in Tumor Diagnosis after Radiation-Induced Stress.
Heneweer C; Peñate Medina T; Tower R; Kalthoff H; Kolesnick R; Larson S; Peñate Medina O
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917976
[TBL] [Abstract][Full Text] [Related]
59. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
Webb MS; Logan P; Kanter PM; St-Onge G; Gelmon K; Harasym T; Mayer LD; Bally MB
Cancer Chemother Pharmacol; 1998; 42(6):461-70. PubMed ID: 9788572
[TBL] [Abstract][Full Text] [Related]
60. Lithocholic acid-based oligomers as drug delivery candidates targeting model of lipid raft.
Wnętrzak A; Szymczuk D; Chachaj-Brekiesz A; Dynarowicz-Latka P; Lupa D; Lipiec EW; Laszuk P; Petelska AD; Markiewicz KH; Wilczewska AZ
Biochim Biophys Acta Biomembr; 2024 Mar; 1866(3):184294. PubMed ID: 38316379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
